logo-loader

Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts

Published: 22:45 13 Nov 2026 AEDT

Immunic Inc (NASDAQ:IMUX) CEO Erik Lundgren talked with Proactive's Stephen Gunnion about the company's third-quarter 2026 performance, upcoming Phase 3 relapsing multiple sclerosis (MS) trial results and initiation of another Phase 3 trial in progressive MS.

Lundgren highlighted December 2026 as a major milestone, with topline results expected from the twin ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing MS. Both studies remain on track, with activities underway for data cleaning, unblinding and results disclosure.

Subject to positive findings, Immunic plans to submit a New Drug Application (NDA) to the US Food and Drug Administration in mid-2027, potentially paving the way for approval in 2028.

The interview also covered preparations for PROTECT-MS, a third Phase 3 trial targeting progressive MS, with first patient enrolment expected in the first half of 2027.

Lundgren discussed Immunic's $132 million cash position at the end of September, providing runway into late 2027, alongside the potential for a further $200 million from outstanding warrants.

He also outlined recent leadership appointments supporting regulatory preparations and potential future commercialisation.

For more interviews and updates from publicly listed companies, visit Proactive's YouTube channel.
Don't forget to like this video, subscribe to Proactive and turn on notifications to stay informed about future interviews, company developments and market updates.

Read Proactive’s Editorial Policy here.

#Immunic #MultipleSclerosis #Phase3Trials #ImmunicInc #ClinicalTrials #RelapsingMS #ProgressiveMS #BiotechStocks #FDA #DrugDevelopment #BiotechNews #HealthcareInvesting #ProactiveInvestors

Immunic Therapeutics Presents Advanced MS Treatment Data at Global Conference

Immunic Therapeutics CEO Dr Daniel Vitt joined Steve Darling from Proactive to discuss the company’s participation at the European Committee for Treatment and Research on Multiple Sclerosis conference, ECTRIMS, the world’s largest event dedicated to multiple sclerosis (MS) research. Dr. Vitt...

on 18/9/24